Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on August 22, 2017. The report details the entry into a material definitive agreement regarding the manufacturing of the company's product candidate, DSUVIA (sufentanil sublingual tablets).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a contractual agreement and does not contain financial performance data.
Material Changes
On August 22, 2017, the Company entered into a second amendment to its Manufacturing Services Agreement (MSA) with Patheon Pharmaceuticals, Inc., effective August 4, 2017. Key changes include:
- Patheon will manufacture, supply, and provide validation and stability services for DSUVIA for the defined Territory (USA, Canada, Mexico, EU, Switzerland, Liechtenstein, Norway, Iceland, and Australia).
- The Company retains the right to purchase the Product in Bulk Tablet Packaging from Patheon for distribution outside the Territory.
- Patheon agreed to perform release and stability testing on Finished Packaged Product provided by a third-party packager managed by the Company.
- All other terms and conditions of the original agreement remain unchanged.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard qualification that the summary is not complete. The full text of the amendment is referenced as an exhibit to be filed in the subsequent Form 10-Q for the quarter ended September 30, 2017.
Investor Verification Checklist
- Verify the full terms of the second amendment to the MSA in the upcoming Form 10-Q filing.
- Confirm the specific pricing and volume commitments within the amended agreement.
- Monitor the status of DSUVIA regulatory approvals and commercial launch timelines.
- Review the Company's cash position in the next quarterly report to assess funding for manufacturing and commercialization.